

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number  
WO 2004/031154 A1

(51) International Patent Classification<sup>7</sup>: C07D 223/16,  
267/14, 281/06, 281/10, 417/04, A61K 31/55, 31/553,  
31/554, A61P 25/28

(21) International Application Number:  
PCT/SE2003/001534

(22) International Filing Date: 2 October 2003 (02.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0202929-6 3 October 2002 (03.10.2002) SE  
0203829-7 18 December 2002 (18.12.2002) SE

(71) Applicant (for all designated States except US): AS-  
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BECKER**, Christo-  
pher [US/US]; AstraZeneca Wilmington, P.O. Box 15437,  
Wilmington, DE 19850-5437 (US). **DEMBOFSKY**,  
Bruce [US/US]; AstraZeneca Wilmington, P.O. Box  
15437, Wilmington, DE 19850-5437 (US). **JACOBS**,  
Robert [US/US]; AstraZeneca Wilmington, P.O. Box  
15437, Wilmington, DE 19850-5437 (US). **KANG**, James  
[US/US]; AstraZeneca Wilmington, P.O. Box 15437,  
Wilmington, DE 19850-5437 (US). **OHNMACHT**, Cyrus  
[US/US]; AstraZeneca Wilmington, P.O. Box 15437,  
Wilmington, DE 19850-5437 (US). **ROSAMOND**, James  
[US/US]; AstraZeneca Wilmington, P.O. Box 15437,

Wilmington, DE 19850-5437 (US). **SHENYI**, Ashokku-  
mar, Bhikkappa [US/US]; AstraZeneca Wilmington, P.O.  
Box 15437, Wilmington, DE 19850-5437 (US). **SIMP-**  
**SON**, Thomas [US/US]; AstraZeneca Wilmington, P.O.  
Box 15437, Wilmington, DE 19850-5437 (US). **WOODS**,  
James [US/US]; AstraZeneca Wilmington, P.O. Box  
15437, Wilmington, DE 19850-5437 (US).

(74) Agent: ASTRAZENECA AB; Global Intellectual Prop-  
erty, S-151 85 Södertälje (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,  
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL LACTAMS AND USES THEREOF



(57) Abstract: Compounds having the formula (I) pharmaceu-  
tical compositions containing them and their methods of use for  
the treatment of neurological disorders related to amyloid  $\beta$  pro-  
tein production and neurological disorders such as Alzheimer's  
disease.. These compounds inhibit  $\gamma$  secretase and thereby inhibit  
the production of amyloid  $\beta$  protein, thereby acting to prevent the  
formation of neurological deposits of amyloid protein.

WO 2004/031154 A1